Merck licenses Portola's betrixaban; returns rights
Portola Pharmaceuticals (cardiovascular diseases, inflammatory conditions, and cancer) has granted Merck exclusive worldwide development and commercialization rights to its Phase II anticoagulant betrixaban.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com